HIV Mutation Detail Information

> L210W Search Result

Mutation Information

Mutation Site	L210W
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Relevant Drug	thymidineanalogue (TAMs)
Country	Australia;Europe;North America

Literature Information

PubMed PMID	31430369
Disease	HIV infection/AIDS
Published Year	2019
Journal	The Journal of antimicrobial chemotherapy
Title	Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Author	Andreatta K,Willkom M,Martin R,Chang S,Wei L,Liu H,Liu YP,Graham H,Quirk E,Martin H,White KL
Evidence	Pre-existing NRTI-R substitutions were observed in 16% (89/543) of BIC/FTC/TAF-treated participants; the most frequently detected substitutions were M184V/I in 10% (54/543) and thymidine analogue mutations (TAMs; M41L, D67N, K70R, L210W, T215Y/F and K219Q/N/E/R) in 8.8% (48/543).

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation